

Supplementary Materials: Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy in Vitro and in Vivo

Yusuf A. Haggag, Kyle B. Matchett, Robert A. Falconer, Mohammad Isreb, Jason Jones, Ahmed Faheem, Paul McCarron and Mohamed El-Tanani




Figure S1. MDA-MB-231 cell viability results of different doses of M 124–135 peptide and M 124–135 peptide-loaded NP (A) and CT 196–210 peptide and CT 196–210 peptide-loaded NP (B) after 24, 48, 72 and 96 h.




Figure S2. MDA-MB-231 cell viability results of different doses of scramble peptide and scramble peptide-loaded NP after 24, 48, 72 and 96 h.




Figure S3. MCF-10a cell viability results of different doses of NT 3-12 peptide and NT 3-12 peptide-loaded NP after 24, 48, 72 and 96 h.



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).